Toxicity of a standardized mistletoe extract in immunocompromised and healthy individuals

American Journal of Therapeutics

Volumn 6, Issue 1, 1999, Pages 37-43

  Van Wely, Madelon ^a   Stoss, Matthias ^a   Gorter, Robert W ^a,b,c,d  

^a Inst Oncological Immunological Res   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

^d NONE   (Germany)

Author keywords

HIV positive; Iscador; Mistletoe therapy; Toxicity

Indexed keywords

ISCADOR QU SPEZIAL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG SAFETY; EOSINOPHILIA; FEVER; FLU LIKE SYNDROME; GINGIVITIS; HERBAL MEDICINE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; SUBCUTANEOUS DRUG ADMINISTRATION; VISCUM ALBUM;

EID: 0032936254     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199901000-00006     Document Type: Article

References (21)

1. Büssing A, Azhari T, Ostendrop H, et al: Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J. Cancer 1994;30A:1836-1841.
2. Bussing A, Regnery A, Schweizer K: Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 1995;94:199-205.
3. Hajto T: Immunomodulatory effects of Iscador: a Viscum album preparation. Oncology 1986;43:51-65.
4. Joller PW, Menrad JM, Schwarz T, et al: Stimulation of cytokine production via a special standardized mistletoe preparation in an in vitro human skin bioassay. Arzneim Forsch Drug Res 1996;46:649-653.
5. Hajto T, Hostanska K, et al: Increased secretion of tumor necrosis factor, interleukin-1 and interleukin-6 by human mononuclear cells exposed to B-Galaktoside-specific lectin from clinically applied mistletoe extract. Cancer Res 1990;50:3322-3326.
6. Beuth J, Ko H, Tunggal L, et al: Vergleichende Untersuchungen zu immunaktiven Wirkung vor Galaktosidspezifischem Mistellektin. Drug Res 1993;43:2.
7. Schaller G, Giannattosio M, Urech K: Cytotoxicity of different viscotoxins and extracts from the European subspecies of viscum album L. Phytother Res 1996;10:473-477.
8. Hajto T, Hostanska K, et al: Modulatory potency of the B-Galaktoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 1989;49:4803-4808.
9. Stein G, Berg PA: Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol 1994;47:33-38.
10. + T cells by rhamnogalacturonan: target cell specificty and activity against NK-insensitive targets. J Cancer Res Clin Oncol 1994;120:383-388.
11. Mueller EA, Anderer FA: Chemical specificity of effector cell/tumor cell bridging by a viscum album rhamnogalacturonan enhancing cytotoxicity of human NK cells. Immunopharmacology 1990;19:69-77.
12. Von Laue HB, Jacobi U: Immunstimulierende Wirkung einer Misteltherapie mit ABNOVA Viscum in der onkologischen Nachsorge. Onkologie 1988;3:68-72.
13. Beuth J, Ko H, Gabius H, et al: Behavior of lymphocytes subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. Clin Invest 1992;70: 658-661.
14. Van Gameren M, Willemse PHB, Mulder NH, et al: Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994;5:1434-1441.
15. Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
16. Whicher J, Spence C: When is serum albumine worth measuring? Ann Clin Biochem 1987;24:572-575.
17. Kroegel C, Virchow JC, Luttmann W, et al: Pulmonary immune cells in health and disease, part 1 and 2. Eur Respir J 1994;7:517-543.
18. Klempner MS, Noring R, Mier JW, et al: An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 1990; 322:959.
19. Lindeman A, Ganser A, Herrmann F, et al: Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 1991;12:2120-2127.
20. Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 1991;9:694-704.
21. Gorter RW, Stein J, Stoss M, et al: Prospektive, longitudinale, Dosiseskalierende, Randomisierte Phase-I/II-Studie mit Iscador QuFrF und Iscador Qu Spezial mite HIV. Positven, Krebspatienten und gesunden, nichtrauchenden Probanden. Forchende Komplementärmedizin 1996;3:169-175.